AR118594A1 - Modificación por ingeniería genética de un anticuerpo para la fijación selectiva a cd47 en tumores - Google Patents

Modificación por ingeniería genética de un anticuerpo para la fijación selectiva a cd47 en tumores

Info

Publication number
AR118594A1
AR118594A1 ARP200100953A ARP200100953A AR118594A1 AR 118594 A1 AR118594 A1 AR 118594A1 AR P200100953 A ARP200100953 A AR P200100953A AR P200100953 A ARP200100953 A AR P200100953A AR 118594 A1 AR118594 A1 AR 118594A1
Authority
AR
Argentina
Prior art keywords
binds
antibody
tumors
genetic engineering
fab portion
Prior art date
Application number
ARP200100953A
Other languages
English (en)
Inventor
Ho Cho
Kandasamy Hariharan
Jeffrey Johnson
Sharmistha Acharya
Jeonghoon Sun
Dan Zhu
Haralambos Hadjivassiliou
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AR118594A1 publication Critical patent/AR118594A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Anticuerpos que comprenden al menos una porción Fab que se fija a CD47 y al menos una porción Fab que se fija al antígeno asociado al tumor (TAA) CD20; en donde la porción Fab que se fija a CD47 exhibe baja afinidad a CD47; y en donde la porción Fab que se fija a CD20 exhibe alta afinidad a CD20; y en donde el anticuerpo se fija selectivamente a CD47 y bloquea la interacción de CD47 con SIRPa en células tumorales, al mismo tiempo que no exhibe una fijación sustancial a CD47 en células normales.
ARP200100953A 2019-04-05 2020-04-03 Modificación por ingeniería genética de un anticuerpo para la fijación selectiva a cd47 en tumores AR118594A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962830335P 2019-04-05 2019-04-05

Publications (1)

Publication Number Publication Date
AR118594A1 true AR118594A1 (es) 2021-10-20

Family

ID=70457134

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP200100954A AR118595A1 (es) 2019-04-05 2020-04-03 Modificación por ingeniería genética de un anticuerpo para la fijación selectiva a cd47 en tumores
ARP200100953A AR118594A1 (es) 2019-04-05 2020-04-03 Modificación por ingeniería genética de un anticuerpo para la fijación selectiva a cd47 en tumores

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP200100954A AR118595A1 (es) 2019-04-05 2020-04-03 Modificación por ingeniería genética de un anticuerpo para la fijación selectiva a cd47 en tumores

Country Status (18)

Country Link
US (2) US20220162330A1 (es)
EP (2) EP3946633A1 (es)
JP (2) JP2022535324A (es)
KR (2) KR20210148290A (es)
CN (2) CN114667168A (es)
AR (2) AR118595A1 (es)
AU (1) AU2020252402A1 (es)
BR (1) BR112021019714A2 (es)
CA (1) CA3134964A1 (es)
CL (1) CL2021002608A1 (es)
CO (1) CO2021013836A2 (es)
EA (1) EA202192729A1 (es)
IL (1) IL286889A (es)
MX (1) MX2021012178A (es)
PE (1) PE20212073A1 (es)
SG (1) SG11202110736VA (es)
TW (2) TW202104260A (es)
WO (2) WO2020206255A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4376884A1 (en) * 2021-07-30 2024-06-05 Ludwig-Maximilians-Universität München Anti-cd47 antibodies and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE13746964T2 (hu) 2012-02-06 2020-01-28 Inhibrx Inc CD47 antitestek és alkalmazási eljárásaik
ES2773107T3 (es) * 2012-10-05 2020-07-09 Kyowa Kirin Co Ltd Composición de proteína heterodimérica
ES2876009T3 (es) * 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
EP4137518A1 (en) * 2013-02-06 2023-02-22 Inhibrx, Inc. Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
US20160009824A1 (en) * 2013-03-15 2016-01-14 Merck Patent Gmbh Tetravalent bispecific antibodies
US10087257B2 (en) * 2014-08-08 2018-10-02 The Board Of Trustees Of The Leland Stanford Junior University SIRP alpha-antibody fusion proteins
ES2751915T5 (es) * 2014-08-15 2022-12-23 Merck Patent Gmbh Proteínas de fusión de inmunoglobulina con SIRP alfa
WO2016109415A1 (en) 2014-12-30 2016-07-07 Celgene Corporation Anti-cd47 antibodies and uses thereof
CN114716552B (zh) * 2016-01-11 2024-05-24 四十七公司 人源化、小鼠或嵌合抗cd47单克隆抗体
US11427632B2 (en) 2016-07-06 2022-08-30 Celgene Corporation Antibodies with low immunogenicity and uses thereof
EP3586872A4 (en) * 2017-02-24 2020-12-30 Chugai Seiyaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION, ANTIG-BINDING MOLECULES, TREATMENT METHODS AND SCREENING METHODS
US20200330590A1 (en) 2017-03-27 2020-10-22 Celgene Corporation Methods and compositions for reduction of immunogenicity
US11518810B2 (en) * 2017-05-08 2022-12-06 Shanghai Jmt-Bio Technology Co., Ltd. Bispecific recombinant protein and use thereof

Also Published As

Publication number Publication date
SG11202110736VA (en) 2021-10-28
CL2021002608A1 (es) 2022-06-10
EP3946633A1 (en) 2022-02-09
WO2020206255A1 (en) 2020-10-08
MX2021012178A (es) 2021-11-04
JP2022528869A (ja) 2022-06-16
EA202192729A1 (ru) 2022-01-13
WO2020206251A1 (en) 2020-10-08
IL286889A (en) 2021-10-31
EP3946634A1 (en) 2022-02-09
US20220340675A1 (en) 2022-10-27
AU2020252402A1 (en) 2021-11-18
KR20210148317A (ko) 2021-12-07
CN114667168A (zh) 2022-06-24
CN114269435A (zh) 2022-04-01
KR20210148290A (ko) 2021-12-07
TW202045550A (zh) 2020-12-16
US20220162330A1 (en) 2022-05-26
AR118595A1 (es) 2021-10-20
BR112021019714A2 (pt) 2021-12-14
TW202104260A (zh) 2021-02-01
CA3134964A1 (en) 2020-10-08
CO2021013836A2 (es) 2022-03-29
PE20212073A1 (es) 2021-10-26
JP2022535324A (ja) 2022-08-08

Similar Documents

Publication Publication Date Title
ES2525477T3 (es) Anticuerpos anti-factor D humanizados
CO2017008462A2 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
CO2019006500A2 (es) Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x
ES2527961T3 (es) Anticuerpos monoclonales humanos para CD70
AR041650A1 (es) Anticuerpos que se unen a polipeptidos ca125/o772p cuando estos se encuentran asociados a las celulas. metodos relacionados
AR066204A1 (es) Inmunoglobulina transcitotica
RS53752B1 (en) ANTITELO PROTIV ILT7
EA202190542A1 (ru) Сконструированные биспецифические белки
WO2007035633A3 (en) Screening assays and methods
TR201910348T4 (tr) Matriks metalloproteinaz 9 için antikorlar.
BR112016004437A2 (pt) métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
NZ720765A (en) Antibodies and methods of use
UY38803A (es) Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y usos de las mismas
MX2020010387A (es) Metodos para detectar y cuantificar fgf21.
BRPI0820885B8 (pt) "anticorpo ou fraguimento do mesmo, célula de hibridoma, polinucleotídeo, polipeptídeo compreendendoum domínio de cadeia pesada ou leve de anticorpo, método para detecção de gravidez em um animal bovino, kit e método de purificação de um antígeno principal associado à gravidez (pag)".
DOP2023000158A (es) Anticuerpo triespecífico dirigido a bcma, gprc5d, y cd3
CL2023001888A1 (es) Anticuerpos multiespecíficos con especificidad para il-4r e il-31.
AR118595A1 (es) Modificación por ingeniería genética de un anticuerpo para la fijación selectiva a cd47 en tumores
PE20232050A1 (es) Anticuerpos anti-cd19 y estructuras car-t
AR122930A1 (es) Anticuerpos de pre-direccionamiento y métodos de uso
BR112021020873A2 (pt) Métodos para tratamento de câncer renal com um anticorpo anti-psma/cd3
ES2535426T3 (es) Anticuerpos anti-TNFα y métodos de uso
AR099604A1 (es) Anticuerpos de metaloproteinasa de matriz 9 y sus métodos de uso